Treatment of small hepatocellular carcinoma with percutaneous ethanol injection

Analysis of prognostic factors in 105 western patients

Riccardo Lencioni, C. Bartolozzi, D. Caramella, A. Paolicchi, M. Carrai, G. Maltinti, A. Capria, A. Tafi, P. F. Conte, G. Bevilacqua

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Background. Percutaneous ethanol injection (PEI) has been used in the Far East for treating small, unresectable hepatocellular carcinoma (HCC). To clarify when treatment with PEI may he best indicated for Western patients with HCC, the authors performed a retrospective analysis of the clinicopathologic factors influencing prognosis. Methods. From December 1987 to August 1994, 105 patients with cirrhosis with HCC received PEI as the sole anticancer treatment. Eighty-two patients had uninodular tumors smaller than 5 cm, and 23 patients had multiple lesions (2-4) smaller than or equal to 3 cm each. All patients were in Child-Pugh class A (n = 64) or B (n = 41). Survival was analyzed according to patient- and tumor-related factors by means of the Kaplan-Meier method. Results. The estimated survival rates of all 105 patients were 96% at 1 year, 86% at 2 years, 68% at 3 years, 51% at 4 years, 32% at 5 years, and 24% at 6 years. Survival was not affected by sex, age, etiology of cirrhosis, or hepatitis B surface antigen or anti-hepatitis C virus positivity, but depended on Child-Pugh class (P = 0.006) and presence of ascites (P = 0.009). Patients with a pretreatment alpha-fetoprotein level of 200 ng/ml or less had a better prognosis than patients with an alpha- fetoprotein level higher than 200 ng/ml (P = 0.007). Patients with uninodular HCC of 3 cm or less had significantly better long term survival (P = 0.04) than patients with uninodular HCC of 3.1-5 cm or with multinodular tumors. Tumor grade according to Edmondson and Steiner and tumor volume, in contrast, did not significantly influence prognosis (P > 0.1). Conclusions. For Western patients with HCC treated with PEI, the prognosis was highly dependent on the severity of the underlying cirrhosis. Treatment with PEI is best indicated for patients with uninodular tumors of 3 cm or less in greatest dimension and an alpha-fetoprotein level lower than 200 ng/ml.

Original languageEnglish (US)
Pages (from-to)1737-1746
Number of pages10
JournalCancer
Volume76
Issue number10
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Ethanol
Injections
Therapeutics
alpha-Fetoproteins
Fibrosis
Neoplasms
Survival
Far East
Hepatitis B Surface Antigens
Tumor Burden
Ascites
Hepacivirus
Statistical Factor Analysis
Survival Rate

Keywords

  • hepatocellular carcinoma
  • percutaneous ethanol injection
  • prognostic factor
  • tumor multiplicity
  • tumor size

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection : Analysis of prognostic factors in 105 western patients. / Lencioni, Riccardo; Bartolozzi, C.; Caramella, D.; Paolicchi, A.; Carrai, M.; Maltinti, G.; Capria, A.; Tafi, A.; Conte, P. F.; Bevilacqua, G.

In: Cancer, Vol. 76, No. 10, 1995, p. 1737-1746.

Research output: Contribution to journalArticle

Lencioni, R, Bartolozzi, C, Caramella, D, Paolicchi, A, Carrai, M, Maltinti, G, Capria, A, Tafi, A, Conte, PF & Bevilacqua, G 1995, 'Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients', Cancer, vol. 76, no. 10, pp. 1737-1746. https://doi.org/10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P
Lencioni, Riccardo ; Bartolozzi, C. ; Caramella, D. ; Paolicchi, A. ; Carrai, M. ; Maltinti, G. ; Capria, A. ; Tafi, A. ; Conte, P. F. ; Bevilacqua, G. / Treatment of small hepatocellular carcinoma with percutaneous ethanol injection : Analysis of prognostic factors in 105 western patients. In: Cancer. 1995 ; Vol. 76, No. 10. pp. 1737-1746.
@article{320b0e2a2f544fda9b9eacf83a11739c,
title = "Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients",
abstract = "Background. Percutaneous ethanol injection (PEI) has been used in the Far East for treating small, unresectable hepatocellular carcinoma (HCC). To clarify when treatment with PEI may he best indicated for Western patients with HCC, the authors performed a retrospective analysis of the clinicopathologic factors influencing prognosis. Methods. From December 1987 to August 1994, 105 patients with cirrhosis with HCC received PEI as the sole anticancer treatment. Eighty-two patients had uninodular tumors smaller than 5 cm, and 23 patients had multiple lesions (2-4) smaller than or equal to 3 cm each. All patients were in Child-Pugh class A (n = 64) or B (n = 41). Survival was analyzed according to patient- and tumor-related factors by means of the Kaplan-Meier method. Results. The estimated survival rates of all 105 patients were 96{\%} at 1 year, 86{\%} at 2 years, 68{\%} at 3 years, 51{\%} at 4 years, 32{\%} at 5 years, and 24{\%} at 6 years. Survival was not affected by sex, age, etiology of cirrhosis, or hepatitis B surface antigen or anti-hepatitis C virus positivity, but depended on Child-Pugh class (P = 0.006) and presence of ascites (P = 0.009). Patients with a pretreatment alpha-fetoprotein level of 200 ng/ml or less had a better prognosis than patients with an alpha- fetoprotein level higher than 200 ng/ml (P = 0.007). Patients with uninodular HCC of 3 cm or less had significantly better long term survival (P = 0.04) than patients with uninodular HCC of 3.1-5 cm or with multinodular tumors. Tumor grade according to Edmondson and Steiner and tumor volume, in contrast, did not significantly influence prognosis (P > 0.1). Conclusions. For Western patients with HCC treated with PEI, the prognosis was highly dependent on the severity of the underlying cirrhosis. Treatment with PEI is best indicated for patients with uninodular tumors of 3 cm or less in greatest dimension and an alpha-fetoprotein level lower than 200 ng/ml.",
keywords = "hepatocellular carcinoma, percutaneous ethanol injection, prognostic factor, tumor multiplicity, tumor size",
author = "Riccardo Lencioni and C. Bartolozzi and D. Caramella and A. Paolicchi and M. Carrai and G. Maltinti and A. Capria and A. Tafi and Conte, {P. F.} and G. Bevilacqua",
year = "1995",
doi = "10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P",
language = "English (US)",
volume = "76",
pages = "1737--1746",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Treatment of small hepatocellular carcinoma with percutaneous ethanol injection

T2 - Analysis of prognostic factors in 105 western patients

AU - Lencioni, Riccardo

AU - Bartolozzi, C.

AU - Caramella, D.

AU - Paolicchi, A.

AU - Carrai, M.

AU - Maltinti, G.

AU - Capria, A.

AU - Tafi, A.

AU - Conte, P. F.

AU - Bevilacqua, G.

PY - 1995

Y1 - 1995

N2 - Background. Percutaneous ethanol injection (PEI) has been used in the Far East for treating small, unresectable hepatocellular carcinoma (HCC). To clarify when treatment with PEI may he best indicated for Western patients with HCC, the authors performed a retrospective analysis of the clinicopathologic factors influencing prognosis. Methods. From December 1987 to August 1994, 105 patients with cirrhosis with HCC received PEI as the sole anticancer treatment. Eighty-two patients had uninodular tumors smaller than 5 cm, and 23 patients had multiple lesions (2-4) smaller than or equal to 3 cm each. All patients were in Child-Pugh class A (n = 64) or B (n = 41). Survival was analyzed according to patient- and tumor-related factors by means of the Kaplan-Meier method. Results. The estimated survival rates of all 105 patients were 96% at 1 year, 86% at 2 years, 68% at 3 years, 51% at 4 years, 32% at 5 years, and 24% at 6 years. Survival was not affected by sex, age, etiology of cirrhosis, or hepatitis B surface antigen or anti-hepatitis C virus positivity, but depended on Child-Pugh class (P = 0.006) and presence of ascites (P = 0.009). Patients with a pretreatment alpha-fetoprotein level of 200 ng/ml or less had a better prognosis than patients with an alpha- fetoprotein level higher than 200 ng/ml (P = 0.007). Patients with uninodular HCC of 3 cm or less had significantly better long term survival (P = 0.04) than patients with uninodular HCC of 3.1-5 cm or with multinodular tumors. Tumor grade according to Edmondson and Steiner and tumor volume, in contrast, did not significantly influence prognosis (P > 0.1). Conclusions. For Western patients with HCC treated with PEI, the prognosis was highly dependent on the severity of the underlying cirrhosis. Treatment with PEI is best indicated for patients with uninodular tumors of 3 cm or less in greatest dimension and an alpha-fetoprotein level lower than 200 ng/ml.

AB - Background. Percutaneous ethanol injection (PEI) has been used in the Far East for treating small, unresectable hepatocellular carcinoma (HCC). To clarify when treatment with PEI may he best indicated for Western patients with HCC, the authors performed a retrospective analysis of the clinicopathologic factors influencing prognosis. Methods. From December 1987 to August 1994, 105 patients with cirrhosis with HCC received PEI as the sole anticancer treatment. Eighty-two patients had uninodular tumors smaller than 5 cm, and 23 patients had multiple lesions (2-4) smaller than or equal to 3 cm each. All patients were in Child-Pugh class A (n = 64) or B (n = 41). Survival was analyzed according to patient- and tumor-related factors by means of the Kaplan-Meier method. Results. The estimated survival rates of all 105 patients were 96% at 1 year, 86% at 2 years, 68% at 3 years, 51% at 4 years, 32% at 5 years, and 24% at 6 years. Survival was not affected by sex, age, etiology of cirrhosis, or hepatitis B surface antigen or anti-hepatitis C virus positivity, but depended on Child-Pugh class (P = 0.006) and presence of ascites (P = 0.009). Patients with a pretreatment alpha-fetoprotein level of 200 ng/ml or less had a better prognosis than patients with an alpha- fetoprotein level higher than 200 ng/ml (P = 0.007). Patients with uninodular HCC of 3 cm or less had significantly better long term survival (P = 0.04) than patients with uninodular HCC of 3.1-5 cm or with multinodular tumors. Tumor grade according to Edmondson and Steiner and tumor volume, in contrast, did not significantly influence prognosis (P > 0.1). Conclusions. For Western patients with HCC treated with PEI, the prognosis was highly dependent on the severity of the underlying cirrhosis. Treatment with PEI is best indicated for patients with uninodular tumors of 3 cm or less in greatest dimension and an alpha-fetoprotein level lower than 200 ng/ml.

KW - hepatocellular carcinoma

KW - percutaneous ethanol injection

KW - prognostic factor

KW - tumor multiplicity

KW - tumor size

UR - http://www.scopus.com/inward/record.url?scp=0028871580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028871580&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P

DO - 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P

M3 - Article

VL - 76

SP - 1737

EP - 1746

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -